View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
Downloadable slides on recent updates in R/R FL, with a focus on bispecific antibodies and CAR T-cell therapy, from Clinical Care Options (CCO)
Ian W. Flinn, MD, PhD
Laurie H. Sehn, MD, MPH
Released: February 2, 2023
Downloadable slides on recent updates in R/R FL, with a focus on second-line therapies and third-line epigenetic modifiers and PI3K inhibitors, from Clinical Care Options (CCO)
Ian W. Flinn, MD, PhD
Laurie H. Sehn, MD, MPH
Released: February 2, 2023
Updated data from the CheckMate 648 study of first-line nivolumab + either chemotherapy or ipilimumab for esophageal SCC, presented at ASCO GI 2023 and reported by Clinical Care Options (CCO)
Stacey Stein, MD, on systemic therapy for advanced hepatocellular carcinoma, including most recent clinical data on first-line and second-line treatment options in this Clinical Care Options (CCO) text module
Stacey Stein, MD
Physicians:
maximum of 1.0 AMA PRA Category 1 Credit™
Released: February 1, 2023
Expired:
January 31, 2024
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
